Rayence Co., Ltd. (KOSDAQ:228850)
6,710.00
-90.00 (-1.32%)
At close: Jun 17, 2026
Rayence Revenue
Rayence had revenue of 36.75B KRW in the quarter ending March 31, 2026, with 34.88% growth. This brings the company's revenue in the last twelve months to 124.23B, up 6.10% year-over-year. In the year 2025, Rayence had annual revenue of 114.72B, down -8.63%.
Revenue (ttm)
124.23B
Revenue Growth
+6.10%
P/S Ratio
0.85
Revenue / Employee
554.59M
Employees
224
Market Cap
105.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 114.72B | -10.84B | -8.63% |
| Dec 31, 2024 | 125.56B | -17.42B | -12.18% |
| Dec 31, 2023 | 142.99B | -4.17B | -2.84% |
| Dec 31, 2022 | 147.16B | 12.59B | 9.36% |
| Dec 31, 2021 | 134.57B | 33.04B | 32.55% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sy Co., Ltd. | 511.55B |
| ActRO | 240.57B |
| MDS Tech | 194.60B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 108.89B |
| OPTUS Pharmaceutical | 91.62B |
| BIOBIJOU | 24.92B |
| Aminologics | 22.68B |
| ONEUL E&M co.,Ltd. | 18.78B |